EMA: First specific replacement therapy to treat rare bleeding disorder

Coagadex recommended for approval for prevention of bleeding episodes for patients with factor X deficiency The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Coagadex (human coagulation factor X) to treat factor X deficiency, a rare inherited bleeding disorder. Coagadex is indicated for the treatment and preventive management of bleeding episodes and the control of bleeding during surgical procedures in patients with hereditary factor X deficiency. The medicine’s active substance is human coagulation factor X, a protein derived from human plasma.